This morning, Sanofi and Provention Bio announced an agreement for Sanofi to acquire Provention Bio, the manufacturer of Tzield (teplizumab-mzwv), for approximately $2.9 billion in cash. 

Tzield is the first and only FDA-approved disease-modifying therapy to delay type 1 diabetes (T1D) onset in people at-risk for developing the disease. 

The announced acquisition of Provention Bio by Sanofi brings the first T1D disease-modifying therapy available in the U.S. into the portfolio of a global leading pharmaceutical company, representing an endorsement of the potential of these types of therapies and, we hope, the opportunity to bring this life-changing therapy and others in the pipeline to more people faster.    

JDRF had a hand in the development of teplizumab from nearly the beginning, supporting early-stage research in the 1980s; funding clinical trials; facilitating regulatory pathways; a strategic investment by the JDRF T1D Fund that brought Provention Bio into T1D for the first time; and advancing commercial development.   

We are pleased to see this move to another stage in this revolutionary partnership.